

# SYMPLIFY

24 November 2022

Dear SYMPLIFY Participant,

We are contacting you on behalf of the University of Oxford, Sponsor of the SYMPLIFY trial, to say thank you for taking part in the study, and to update you on the progress that has been made since you signed up to take part last year.

SYMPLIFY is designed to help develop a new blood test for early identification of different types of cancer. Cancer is easier to treat if it is diagnosed early. In SYMPLIFY we are checking the performance of a new test, known as Galleri™ which detects DNA from cancers in the blood. SYMPLIFY recruitment was very successful with over 6000 people referred by their GP to check if their symptoms were due to cancer signing up between July and November, 2021. The SYMPLIFY team are comparing the results of the Galleri™ test with the diagnosis made in the NHS to see how well the test performs. To do this we will follow-up what happens to your health by accessing your data held centrally by the NHS. We are writing to you today to remind you of your rights and where you can find more information about these.

The SYMPLIFY team at the University of Oxford will be using information from you and from your medical records to undertake this study. The University of Oxford acts as the data controller for this study. This means that the University of Oxford is responsible for looking after your information and using it properly. Data protection regulation requires that we state the legal basis for processing information about you. In the case of research, this is 'a task in the public interest'. Some of your information will also be sent to GRAIL, LLC in the United States but this will be pseudonymised data - data that is linked to a code number instead of your name or other identifiable details. Some countries, including the United States, have been found by the European Commission not to offer the same level of data protection as that found in the European Economic Area. Therefore, GRAIL, the NHS, and the University of Oxford have entered into a data transfer agreement in a form approved by the European Commission to make sure that your information remains protected after it is sent to GRAIL. Please contact the SYMPLIFY team if you wish to obtain a copy of the standard data transfer agreement. For more information or to learn about how to withdraw consent for sharing pseudonymised data with GRAIL, please follow this link: <https://www.oncology.ox.ac.uk/clinical-trials/oncology-clinical-trials-office-octo/current-trials/symplify> If you would prefer for your pseudonymised data not to be sent to GRAIL please use the link in the next 4 weeks to let the SYMPLIFY team know. If you are happy for your pseudonymised data to be sent to GRAIL then you don't need to do anything.

The study team will publish the SYMPLIFY results in 2023 in academic journals and as publicly accessible resources. We hope the results of SYMPLIFY will lead to improvements in the way cancer is diagnosed for all patients in the NHS. Many thanks again for your invaluable contribution to the success of SYMPLIFY.

Yours faithfully,



Professor Mark Middleton  
SYMPLIFY Chief Investigator



Dr Brian Nicholson  
SYMPLIFY Lead Investigator